Infections in solid organ transplant recipients

Current Opinion in Infectious Diseases

Volumn 11, Issue 4, 1998, Pages 411-417

  Singh, Nina ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; COLISTIN; FAMCICLOVIR; FLUCONAZOLE; GANCICLOVIR; INTERLEUKIN 2; LAMIVUDINE; PYRROLE DERIVATIVE; RIBAVIRIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ASPERGILLOSIS; BACTERIAL INFECTION; CANDIDIASIS; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; GRAFT INFECTION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS G VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; ORGAN TRANSPLANTATION; REVIEW; VIRUS INFECTION;

EID: 0031855047     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199808000-00003     Document Type: Review

References (43)

1. Dockrell DH, Prada J, Jones MF, Patel R, Badley AD, Harmsen WS. et al. • Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis 1997; 176:1135-1140. Pnmary HHV-6 infection was shown to be a predictor of tissue-invasive CMV disease in liver transplant recipients.
2. Singh N, Carrigan DR, Gayowski T, Marino IR. Human herpesvirus-6 infection in liver transplant recipients: documentation of pathogenicity. Transplantation 1997; 64:674-678.
3. DesJardin JA, Falagas ME, Gibbons L, Levy S, Ablashi DV, Werner BG. Snydman DR. Human herpesvirus-6 infection is associated with development of primary cytomegalovirus infection and CMV disease in kidney transplantation [abstract H-116]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada; 1997.
4. Chang FY, Singh N, Gayowski T, Wagener MM, Marino IR. Fever in liver • transplant recipients: changing spectrum of etiologic agents. Clin Infect Dis 1998; 26:59-65. This study documented that rejection and CMV were no longer a significant cause of febrile illnesses after liver transplantation.
5. Randhawa PS, Jenkins FJ, Nalesnik MA, Martens J, Williams PA, Ries A, et al. Herpesvirus 6 variant A infection after heart transplantation with giant cell transformation in bile ductular and gastroduodenal epithelium. Am J Surg Pathol 1997; 21:847-853.
6. Isomura H, Yamada M, Yoshida M, Tanaka H, Kitamura T, Oda M, et al. Suppressive effects of human herpesvirus 6 on in vitro colony formation of hematopoietic progenitor cells. J Med Virol 1997; 52:406-412.
7. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia J, Bowden RA. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantatton. Transplantation 1997; 64:108-113.
8. Brennan DC, Garlock KA, Lippman BJ, Buller RS, Gaudreault-Keener M, Lowell JA, et al. Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients. Transplant Proc 1997; 29:809-811.
9. McCartney M, Gane EJ, Portmann B, Williams R. Comparison of a new quantitative cytomegalovirus DNA assay with other detection methods. Transplantation 1997; 63:1803-1807.
10. Kusne S, Manez R, Frye BL, St George K, Abu-Elmagd K, Tabasco-Menguillon J, et al. Use of DNA amplification for diagnosis of cytomegalovirus enteritis after intestinal transplantation. Gastroenterology 1997; 112:1121-1128.
11. MacDonald GA, Greenson JK, DelBuono EA, Grady WM, Merion RM, Frank TS, et al. Mini-microabscess syndrome in liver transplant recipients. Hepatology 1997; 26:192-197.
12. Singh N, Yu VL, Gayowski T, Marino IR. Cytomegalovirus antigenemia guided preemptive therapy with oral versus intravenous ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients [Abstract H57]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997; Toronto, Canada; September.
13. Duvoux C, Challine-Lehmann D, Pawlotsky JM, Metreau JM, Cherqui D, Duval J, Dhumeaux D. Preemptive treatment of CMV infection after liver transplantation using oral ganciclovir: preliminary results. Hepatology 1997; 26:158A.
14. Bajjoka I, Baliad P, Brown K, May E, Escobar F, Mozes M, Abouljoud M. Intravenous versus oral ganciclovir in the prevention of CMV infection and disease in liver transplant recipients. Hepatology 1997; 26:157A.
15. Alain S, Honderlick P, Grenet D, Stern M, Vadam C, Sanson-LePons MJ, • Mazeron MC, Failure of ganciclovir treatment associated with selection of a ganciclovir resistant cytomegalovirus strain in a lung transplant recipient. Transplantation 1997; 63:1533-1536. Prolonged ganciclovir therapy was shown to be associated with the selection of ganciclovir-resistant CMV mutant and the progression of CMV disease.
16. Manez R, Breinig MC, Linden P, Wilson J, Torre-Cisneros J. Kusne S, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease, J Infect Dis 1997; 176:1462-1467.
17. Dockrell DH, Strickler JG, Paya CV. Epstein-Barr virus-induced T cell lymphoma in solid organ transplant recipients. Clin Infect Dis 1998; 26:180-182.
18. Nalesnik MA, Rao AS, Furukawa H, Pham S, Zeevi A, Fung JJ, et al. • Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997; 63:1200-1205. In this study lymphokine-activated killer cells led to the regression of EBV-positive PTLDs. These data, although preliminary, appear promising.
19. Stark K, Meyer CG, Tacke M, Schwarz A, Braun C, Huzly D, et al. Hepatitis G virus RNA and hepatitis G virus antibodies in renal transplant recipients. Transplantation 1997; 64:608-612.
20. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. Lack of evidence for hepatitis G virus replication in the livers of patients coinfected with hepatitis C and G viruses. J Virol 1997; 71:7804-7806.
21. Cotler SJ, Gretch D, Bronner MP. Hepatitis G virus co-infection does not alter the course of recurrent hepatitis C virus infection in liver transplantation recipients. Hepatology 1997; 26:432-436.
22. Vargas HE,1 Laskus T, Radkowski M, Poutous A, Wang L, Lee R. et al. Hepatitis G virus coinfection in hepatitis C virus-infected liver transplant recipients. Transplantation 1997; 64:786-788.
23. Dickson RC, Qian K, Lau JYN, High prevalence of GB virus-C/hepatitis G virus infection in liver transplant recipients. Transplantation 1997; 63:1695-1697.
24. Dussol B, Charrel R. Lamballerie XD, Berthezene P, Brunet P, DeMicco P, et al. Prevalence of hepatitis G virus infection in kidney transplant recipients. Transplantation 1997; 64:537-539.
25. Pessoa MG, Terrault NA, Ferrell LD, Kim JP, Kolberg J, Detmer J, et al. Hepatitis G virus in patients with cryptogenic liver disease undergoing liver transplantation. Hepatology 1997; 25:1266-1270.
26. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26:500-504.
27. Singh N, Gayowski T, Wannstedt CF, Shakil O, Wagener MM, Fung JJ, Marino IR. Interferon-z for prophylaxis of recurrent viral hepatitis C in liver transplant recipients. Transplantation 1998; 65:82-86.
28. Fang JC, Hespenheide EE, Driscoll CJ. Caldwell SH. Amantadine-HCI treatment of chronic hepatitis C. Hepatology 1997; 26:217A.
29. Al Faraidy KA, Yoshida EM, Davis JE, Vartanian RK, Anderson FH, Steinbrecher UP. Alteration of the dismal natural history of fibrosing cholestatis hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997; 64:926-928.
30. Singh N, Gayowski T, Wannstedt CF, Wagener MM, Marino IR. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 1997; 63:1415-1419.
31. Boeker KHW, Wedemeyer H, Pethig K, Vollmar J, Schuler A, Griffin K, et al. Famciclovir for the treatment of chronic hepatitis B in heart transplant recipients. Hepatology 1997; 26:429A.
32. Locarini SA, Aye TT, Shaw T, DeMan R, Angus PW, McCaughan GW. Bartholomeusz AI. The emergence of famciclovir resistant mutations in the hepatitis B virus polymerase during therapy in patients following liver transplantation. Hepatology 1997; 20:368A.
33. Bauldoff GS, Nunley DR, Manzetti JD, Dauber JH, Keenan RJ. Use of • aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation. Transplantation 1997; 64:748-752. In this study aerosolized colistin and the elimination of intravenous antibiotics led to colonization with the sensitive strains of Pseudomonas.
34. Singh N, Gayowski T, Wagener MM, Marino IR. Predictors and outcome of early versus late-onset major bacterial infections in liver transplant recipients receiving tacrolimus (FK506) as primary immunosuppression. Eur J Clin Microbiol Infect Dis 1997; 16:821-826.
35. Mutimer D, Mirza D, Shaw J, O'Donnell K, Elias E. Enhanced (cytomegalovirus) viral replication associated with septic bacterial complications in liver transplant recipients. Transplantation 1997; 63:1411-1415.
36. Aguado JM, Herrero JA, Gavalda J, Torre-Cisneros J, Blanes M, Rufi G, et al. and the Spanish Transplantation Infection Study Group. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Transplantation 1997; 63:1278-1286
37. Antony SJ, Ynares C, Dummer JS. Isoniazid hepatotoxicity in renal transplant recipients. Clin Transplant 1997; 11:34-37.
38. Selby R. Ramirez CB, Singh R, Kleopoulos I, Kusne S, Starzl TE, Fung J. Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression. Arch Surg 1997; 132:304-310.
39. Singh N, Arnow PM, Bonham A, Dominguez E, Paterson DL, Pankey GA, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64:716-720.
40. Paradowski LJ. Saprophytic fungal infections and lung transplantation-revisited. J Heart Lung Transplant 1997; 16:524-531.
41. Fortun J, Lopez-San Roman A, Velasco JJ, Sanchez-Sousa A, DeVincente E, Nuno J, et al. Susceptibility of Candida glabrata strains with reduced susceptibility of azoles in four liver transplant patients with invasive candidiasis. Eur J Clin Microbiol Infect Dis 1997; 16:314-318.
42. Platz KP, Mueller AR, Rossaint R, Steinmiller T, Lemmens HP, Lobeck H, Neuhaus P. Cytokine pattern during rejection and infection after liver transplantation - improvements in postoperative monitoring. Transplantation 1997; 62:1441-1450.
43. Staehler M, Hammer C, Meiser B, Reichart B. Procalcitonin, a new marker for differential diagnosis of acute rejection and bacterial infection in heart transplantation. Transplant Proc 1997; 29:584-585.